Every 10-Q that Krystal Biotech, Inc. (KRYS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KRYS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRYS filings page.
Krystal Biotech, Inc. reported strong profitability for the quarter ended March 31, 2026, driven by rapid uptake of its gene therapy VYJUVEK. Product revenue, net rose to $116.4 million from $88.2 million a year earlier, largely from growth in Europe and Japan.
Gross margin was 95%, while net income increased to $55.9 million from $35.7 million. Diluted net income per share was $1.83, up from $1.20. Cash, cash equivalents and short-term investments totaled about $823.4 million, and the company reported retained earnings of $80.1 million, highlighting a solid balance sheet to fund its expanding clinical pipeline across ophthalmology, respiratory, dermatology, oncology and aesthetics.
Krystal Biotech (KRYS) reported strong Q3 2025 results, driven by continued commercialization of VYJUVEK. Product revenue, net reached $97.8 million, up from $83.8 million a year ago, with a 96% gross margin. Income from operations rose to $41.4 million from $22.5 million. A tax benefit contributed to net income of $79.4 million versus $27.2 million last year, and diluted EPS increased to $2.66 from $0.91.
For the nine months, product revenue, net totaled $282.0 million (vs. $199.4 million), with net income of $153.4 million. The company released $48.4 million of valuation allowance on deferred tax assets, reflecting improved profitability. Liquidity remained solid with $392.6 million in cash and cash equivalents, $338.5 million in short‑term investments, and $133.1 million in long‑term investments as of September 30, 2025.
Accounts receivable were $129.6 million with concentration in two customers (Customer A 71%, Customer B 16%). Shares outstanding were 28,984,000 as of September 30, 2025, and 28,997,519 as of October 29, 2025.
Krystal Biotech (KRYS) 10-Q – Q2 2025 highlights
- Revenue: VYJUVEK® drove net product revenue to $96.0 m (+37% YoY); H1 2025 revenue reached $184.2 m (+60%).
- Profitability: Gross margin held at 93%. Income from operations leapt to $39.3 m (vs $8.6 m), thanks to higher sales and the absence of 2024 litigation charges. Net income was $38.3 m ($1.29 diluted EPS) versus $15.6 m ($0.53).
- Cash & Investments: Cash, cash equivalents and short-term investments rose to $682.0 m; total liquidity including long-term investments is $820.8 m. The company expects current resources to fund operations for ≥12 months.
- Expenses: R&D fell 8% YoY to $14.4 m as manufacturing timing shifted; SG&A climbed 27% to $35.2 m reflecting commercial build-out. No litigation settlement expense this quarter (-$12.5 m YoY).
- Balance sheet: Stockholders’ equity surpassed $1.04 bn. Accounts receivable stood at $111.4 m, with ~78% concentrated in one customer.
- Pipeline progress: Multiple Phase 1/2 studies (KB407 CF, KB408 AATD, KB707 oncology, KB803 & KB801 ophthalmology) are enrolling; first EU & Japan launches of VYJUVEK expected H2 2025.
- Risks: DOJ subpoenas regarding genetic-testing program; outcome unknown. Heavy reliance on single product and customer concentration noted.